Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Lim, Chai K ^a,b   Bilgin, Ayse ^a   Lovejoy, David B ^a   Tan, Vanessa ^a   Bustamante, Sonia ^b   Taylor, Bruce V ^c   Bessede, Alban ^d   Brew, Bruce J ^e,f   Guillemin, Gilles J ^a,e  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d Immusmol   (France)

^e St Vincent's Centre for Applied Medical Research   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KYNURENINE;

ADULT; BLOOD; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPUTER SIMULATION; DEMOGRAPHY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; COHORT STUDIES; COMPUTER SIMULATION; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, INNATE; KYNURENINE; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 85011588809     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41473     Document Type: Article

References (42)

1. Trapp, B. D. & Nave, K. A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31, 247-269 (2008).
2. Weiner, H. L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65, 239-248 (2009).
3. O'Connor, J. C. et al. Interferon-γ and Tumor Necrosis Factor-α Mediate the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-Like Behavior in Mice in Response to Bacillus Calmette-Guérin. The Journal of Neuroscience 29, 4200-4209 (2009).
4. Guillemin, G. J. et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 21, 1097-1101 (2001).
5. Guillemin, G. J. Quinolinic acid, the inescapable neurotoxin. FEBS J 279, 1356-1365 (2012).
6. Guillemin, G. J., Smythe, G., Takikawa, O. & Brew, B. J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49 (2005).
7. Guillemin, G. J. et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78, 842-853 (2001).
8. Miranda, A. F., Boegman, R. J., Beninger, R. J. & Jhamandas, K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78, 967-975 (1997).
9. Foster, A. C., Vezzani, A., French, E. D. & Schwarcz, R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 48, 273-278 (1984).
10. Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511, 184-190 (2014).
11. Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature medicine 6, 67-70 (2000).
12. Salter, M. G. & Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438, 1167-1171 (2005).
13. Lim, C. K., Bruce, B. J. & Guillemin, G. J. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. International Journal of Tryptophan Research 3, 157-167 (2010).
14. Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C. & Killestein, J. Body fluid biomarkers for multiple sclerosis[mdash]the long road to clinical application. Nat Rev Neurol 11, 585-596 (2015).
15. Lim, C. K. et al. Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity. Autism research: official journal of the International Society for Autism Research (2015).
16. Jones, S. P. et al. Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLoS One 10, e0131389 (2015).
17. Smythe, G. A. et al. Concurrent Quantification of Quinolinic, Picolinic, and Nicotinic Acids Using Electron-Capture Negative-Ion Gas Chromatography-Mass Spectrometry. Analytical Biochemistry 301, 21-26 (2002).
18. Braidy, N., Lim, C. K., Grant, R., Brew, B. J. & Guillemin, G. J. Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis. Brain research 1537, 267-272 (2013).
19. Khan, A. Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. Journal of proteomics 75, 4802-4819 (2012).
20. Hastie, T., Tibshirani, R., Friedman, J. & Franklin, J. The elements of statistical learning: data mining, inference and prediction. The Mathematical Intelligencer 27, 83-85 (2005).
21. Han, J., Kamber, M. & Pei, J. Data mining: concepts and techniques: concepts and techniques (Elsevier, 2011).
22. Team, R.C. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2012. (ISBN 3-900051-07-0, 2014).
23. Venables, W. & Ripley, B. Modern applied statistics with S. Statistics and computing (2002).
24. Grant, R. S., Coggan, S. E. & Smythe, G. A. The Physiological Action of Picolinic Acid in the Human Brain. International Journal of Tryptophan Research: IJTR 2, 71-79 (2009).
25. Mancuso, R. et al. Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. PLoS One 10, e0130715 (2015).
26. Aeinehband, S. et al. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, behavior, and immunity 51, 47-55 (2016).
27. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4, 762-774 (2004).
28. Quintana, F. J. et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 107, 20768-20773 (2010).
29. Kwidzinski, E. et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. The FASEB Journal 19, 1347-1349 (2005).
30. Correale, J., Ysrraelit, M. C. & Gaitan, M. I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132, 1146-1160 (2009).
31. Mohr, D. C., Goodkin, D. E., Islar, J., Hauser, S. L. & Genain, C. P. TReatment of depression is associated with suppression of nonspecific and antigen-specific th1 responses in multiple sclerosis. Archives of Neurology 58, 1081-1086 (2001).
32. Farez Mauricio, F. et al. Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell 162, 1338-1352 (2015).
33. Steiner, J. et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? Journal of Neuroinflammation 8, 1-9 (2011).
34. Guillemin, G. J., Smythe, G., Takikawa, O. & Brew, B. J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23 (2005).
35. Sundaram, G. et al. Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. Journal of Neuroinflammation 11, 204 (2014).
36. Stone, T. W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309-379 (1993).
37. Guidetti, P. & Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11, 3857-3863 (1999).
38. Chiarugi, A., Cozzi, A., Ballerini, C., Massacesi, L. & Moroni, F. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687-695 (2001).
39. Cocco, E. et al. 1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology - Neuroimmunology Neuroinflammation 3 (2016).
40. Raison, C. L. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-[alpha]: relationship to CNS immune responses and depression. Molecular psychiatry 15, 393-403 (2010).
41. Midttun, O., Hustad, S. & Ueland, P. M. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry: RCM 23, 1371-1379 (2009).
42. Chen, Y. & Guillemin, G. J. Kynurenine Pathway Metabolites in Humans: Disease and Healthy States. International Journal of Tryptophan Research 2, 1-19 (2009).